Press release
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies
NanoViricides, Inc., a clinical-stage biotechnology company, is revolutionizing the fight against viral diseases with its proprietary nanomedicine platform. At the forefront of their research is NV-387, a broad-spectrum antiviral drug that promises to address a wide range of critical viral infections, including COVID-19, respiratory syncytial virus (RSV), influenza, and Mpox/smallpox. This innovative solution underscores NanoViricides' commitment to advancing antiviral therapies and meeting significant unmet medical needs globally.
NV-387: A Disruptive Antiviral Technology
NV-387 exemplifies NanoViricides' innovative approach to antiviral therapy. The drug leverages a novel "Re-Infection Blocker" mechanism that mimics natural human cellular structures to directly neutralize viruses. This strategy prevents the virus from binding to healthy cells, halting its ability to replicate and spread. Unlike traditional treatments that target specific viral proteins, NV-387's mechanism is effective across a broad spectrum of viruses, including those with mutating strains, making it a versatile and highly adaptive solution
In preclinical studies, NV-387 demonstrated remarkable efficacy, surpassing established antiviral drugs like Tamiflu Registered and Xofluza Registered in treating influenza. It also completely cured lethal RSV infections in animal models, which is particularly significant as no approved treatment currently exists for RSV
These results highlight the drug's potential as a groundbreaking solution to combat some of the most persistent and dangerous viral diseases.
Addressing Critical Unmet Needs in RSV Treatment
Image: https://www.abnewswire.com/uploads/c716f7b6c36beefab6e264bc2f59bc23.jpg
RSV poses a severe health threat, especially to infants, the elderly, and immunocompromised individuals. Despite its prevalence, the market has lacked a safe and effective treatment option. NV-387 has shown immense promise in addressing this unmet need. In animal models, the drug not only ensured survival but also prevented lung damage, a critical advancement in RSV therapy.
The pediatric RSV treatment market alone is projected to be worth billions of dollars annually in the United States. With NV-387's advancement into Phase II clinical trials, NanoViricides is positioned to tap into this lucrative market while providing life-saving treatment to vulnerable populations
A Versatile Solution for Pandemic Preparedness
The COVID-19 pandemic underscored the need for rapid-response antiviral therapies capable of addressing emerging viral threats. NV-387's broad-spectrum efficacy makes it a vital tool for pandemic preparedness. Its ability to neutralize multiple viruses, including novel and mutating strains, positions it as a cornerstone of global healthcare defense systems.
Unlike vaccines, which target specific viral proteins prone to mutation, NV-387 disrupts the virus's entry mechanism, rendering it effective regardless of genetic variations. This adaptability ensures its utility in combating not only existing viruses but also future pandemics
Broadening the Pipeline: NanoViricides' Holistic Vision
Beyond NV-387, NanoViricides is developing a range of nanomedicine-based antiviral therapies targeting diverse diseases. These include:
1.Herpes Virus Treatments: NV-HHV-1 is being designed to address shingles, cold sores, and genital herpes.
2.Influenza Variants: NV-387 has shown strong efficacy against H1N1 and H5N1 strains in preclinical studies.
3.Future Viral Threats: The platform is flexible enough to adapt to emerging viruses, including dengue, rabies, and Ebola.
NanoViricides' approach emphasizes addressing global health challenges comprehensively. By targeting a wide range of viral diseases, the company is creating a pipeline that combines versatility with efficacy.
Collaborations and Funding
NanoViricides' success in advancing NV-387 is supported by strategic collaborations and innovative funding mechanisms. Partnering with Karveer Meditech Pvt. Ltd. in India, the company conducted successful Phase I clinical trials, establishing the drug's safety and tolerability
Moving forward, NanoViricides plans to expand its clinical trials to additional indications, including influenza and long COVID. To support these developments, the company is pursuing non-dilutive funding options such as grants and partnerships. This approach ensures sustainable growth while advancing its groundbreaking therapies
NV-387's Regulatory Pathway
The regulatory journey for NV-387 is well-defined, with Phase II clinical trials focusing on RSV in adults as a precursor to pediatric approval. Additionally, NanoViricides aims to explore the drug's potential in other viral indications, including Mpox and smallpox. This strategic progression aligns with the company's mission to deliver life-changing therapies to patients globally
Leadership Perspective
Dr. Anil Diwan, President and Executive Chairman of NanoViricides, views NV-387 as a revolutionary development in antiviral medicine. "Our goal is to address the greatest challenge in antiviral therapy-viral resistance. With NV-387, we have created a drug that viruses are highly unlikely to escape, paving the way for a new era in infectious disease treatment," Dr. Diwan stated.
Shaping the Future of Antiviral Medicine
Image: https://www.abnewswire.com/uploads/d3d6d860d1723ff56f1b02dcd1547ab6.jpg
NanoViricides' innovative nanomedicine platform and its lead drug candidate, NV-387, are poised to reshape the landscape of antiviral therapies. By addressing critical unmet needs and preparing for future pandemics, the company is setting a new standard in global healthcare.
For more information about NanoViricides and its groundbreaking research, visit their official website [https://www.nanoviricides.com/].
NanoViricides' advancements in antiviral therapy signify a paradigm shift in how viral diseases are treated. With NV-387 leading the charge, the company continues to pioneer solutions that hold the promise of improving millions of lives worldwide.
https://www.nanoviricides.com/
https://profiles.smallcapsdaily.com/nnvc/
Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
Media Contact
Company Name: EDM Media
Contact Person: Steve Sandifer
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nanoviricidesamexnnvc-leads-innovation-in-broadspectrum-antiviral-therapies]
Phone: +1-214-435-3758
Address:1750 N. Collins Blvd. Suite 101-V
City: Richardson
State: TX 75080
Country: United States
Website: https://www.nanoviricides.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies here
News-ID: 3757738 • Views: …
More Releases from ABNewswire
South Charlotte's Silent Threat: Best Option Restoration Advocates for Professio …
For residents dealing with suspected mold, finding a trusted provider is essential. Searching for "mold removal near me" often leads homeowners to local experts like Best Option Restoration, who offer prompt and thorough inspections. Their team uses advanced tools, such as moisture meters and thermal imaging cameras, to detect hidden mold behind walls, under flooring, or in attics.
Mold growth in homes is often referred to as a "silent threat" because…
Hidden Home Hazard: Best Option Restoration Urges South Charlotte Homeowners to …
The unique climate of the region can exacerbate mold issues, as high humidity provides ideal conditions for spores to thrive. Professional mold remediation South Charlotte involves more than just removing visible mold; it requires addressing the underlying moisture source, containing affected areas to prevent cross-contamination, and using advanced techniques like HEPA filtration and antimicrobial treatments.
In the aftermath of flooding, South Charlotte homeowners often focus on visible water damage, overlooking one…
After the Storm: Best Option Restoration Sees Spike in Calls for Professional Wa …
When storms hit, they often leave a trail of water intrusion that can compromise foundations, walls, and flooring. The immediate priority is to extract standing water and begin the drying process. This is where the value of a dedicated emergency water damage restoration service becomes evident. Best Option Restoration offers 24/7 availability, deploying trained technicians equipped with industrial-grade extractors, air movers, and dehumidifiers.
In the wake of recent severe weather events,…
Why More Ames Residents Trust Pet Medical Center for Emergency Vet Services & Co …
Not all veterinary clinics are equipped to handle exotic animals, but Pet Medical Center stands out as a trusted exotic vet in the area. Birds, reptiles, and small mammals require specialized knowledge, and their team has the training to provide proper diagnostics and treatment. Whether it's a sick guinea pig or an injured lizard, exotic pet owners can trust they're in capable hands.
When a pet emergency strikes, Ames residents need…
More Releases for NanoViricides
NanoViricides Reports NV-387's Anti-Inflammatory Effects Could Combat Viral-Indu …
NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place," said Anil R. Diwan, Ph.D., President and Chairman, adding, "NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on…
Nanostructured Drug Market Exclusive Report with Detailed Study Analysis | Nanov …
The latest qualitative research report (2025-2032) on the Nanostructured Drug Market, published by Coherent Market Insights, provides an in-depth analysis of key market trends, drivers, challenges, and competitive dynamics. It evaluates market size, revenue, production, and CAGR through validated methodologies to ensure accuracy. This report highlighting technological innovations, pricing shifts, consumer preferences, and investment opportunities, the report enables strategic and informed business decisions.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/1841
Focused on growth and…
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotec …
NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.
NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections-potentially creating the first "empiric antiviral therapy"…
Nanomedicines Market Prediction and Analysis Offered By New Study | Abbott, GE H …
The primary goal of the Nanomedicines Market report is to provide readers with a low-cost understanding of the industry that has been examined utilising primary and secondary research methods. This Nanomedicines Market report's primary goal is to provide a comprehensive overview and strategic analysis of the parent industry. The research comprehensively analyses each segment as well as any associated sub-segments that are present in the market. By analysing the market's…
Ebola Treatment Market Projected to Show Strong Growth | GlaxoSmithKline, NanoVi …
HTF MI Analyst have added a new research study on Title Ebola Treatment Market - Global Outlook and Forecast 2021-2027 with detailed information of Product Types [Vaccine (Under Trials) & Drugs (Under Trials)], Applications [Hospitals, Ambulatory Surgery Centres, Specialized Clinics & Army Camps (Veteran Facilities)] & Key Players Such as Arbutus Biopharma, GlaxoSmithKline, Johnson & Johnson Services, Hemispherx Biopharma, BioCryst Pharmaceuticals, NanoViricides, NewLink Genetics, Chimerix, Sarepta Therapeutics & Mapp Biopharmaceutical…
Investigation announced for NYSE: NNVC shares over potential Wrongdoing at NanoV …
An investigation on behalf of investors in shares of NanoViricides, Inc. (NYSE: NNVC) was announced over potential breaches of fiduciary duties by certain officers and directors at NanoViricides, Inc.
Investors who purchased shares of NanoViricides, Inc. (NYSE: NNVC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain NanoViricides, Inc. (NYSE: NNVC officers and directors…
